CRISPR and Gene Augmentation Rescue Trabecular Meshwork Dysfunction in iPSC Models of Lowe Syndrome
Open Access
- 9 September 2026
- journal article
- research article
- Published by Wiley in Advanced Science
- p. e77704
Abstract
Lowe syndrome is a rare, currently incurable multisystem disorder that affects the eyes, kidneys, and central nervous system. It is caused by mutations in the OCRL gene, which encodes an inositol 5‐phosphatase. The disorder remains incurable, and the pathways underlying the ocular symptoms remain poorly understood, largely due to the lack of appropriate models. In this study, trabecular meshwork cell models of Lowe syndrome were generated to test two distinct gene therapy strategies: a mutation‐agnostic OCRL DNA augmentation therapy and a patient‐specific CRISPR‐mediated gene correction strategy. The results showed that AAV2‐OCRL demonstrated the highest transduction efficiency in patient iPSC‐derived trabecular meshwork models (iHTM) among the three AAV‐OCRL vectors evaluated, establishing it as a promising delivery vector. Targeted CRISPR‐based gene therapy restored OCRL enzyme activity and corrected cellular defects in patient iPSC‐derived trabecular meshwork cell models. Furthermore, RNA‐sequencing analysis of these models revealed dysregulation of extracellular matrix organization, cell adhesion, focal adhesion, and cytoskeletal regulatory pathways, suggesting that disruption of interconnected ECM‐adhesion‐cytoskeletal networks may contribute to trabecular meshwork dysfunction in Lowe syndrome‐associated glaucoma. These findings indicate the feasibility of OCRL gene augmentation and CRISPR‐based gene editing in patient‐derived ocular models and position AAV2‐OCRL as a leading therapeutic candidate for Lowe syndrome.Keywords
Funding Information
- National Eye Institute (R01EY036685)
- National Eye Institute (R01‐EY025295)
- National Eye Institute (R01‐EY032159)
- National Eye Institute (R38EY037090)
- U.S. Department of Veterans Affairs (VAI01CX001481)
This publication has 50 references indexed in Scilit:
- The phosphoinositide 3-kinase inhibitor alpelisib restores actin organization and improves proximal tubule dysfunction in vitro and in a mouse model of Lowe syndrome and Dent diseaseKidney International, 2020
- The trabecular meshwork: Structure, function and clinical implications. A review of the literatureJournal Français d'Ophtalmologie, 2020
- Tropomodulins Control the Balance between Protrusive and Contractile Structures by Stabilizing Actin-Tropomyosin FilamentsCurrent Biology, 2020
- The aqueous humor outflow pathways in glaucoma: A unifying concept of disease mechanisms and causative treatmentEuropean Journal of Pharmaceutics and Biopharmaceutics, 2015
- The Inositol 5-Phosphatase dOCRL Controls PI(4,5)P2 Homeostasis and Is Necessary for CytokinesisCurrent Biology, 2011
- From lowe syndrome to Dent disease: correlations between mutations of the OCRL1 gene and clinical and biochemical phenotypesHuman Mutation, 2010
- Adeno-associated virus-2 and its primary cellular receptor—Cryo-EM structure of a heparin complexVirology, 2009
- Cataracts and Glaucoma in Patients With Oculocerebrorenal SyndromeArchives of Ophthalmology (1950), 2003
- Regulation of TIGR/MYOC gene expression in human trabecular meshwork cellsEye, 2000
- Carrier Assessment in Families with Lowe Oculocerebrorenal Syndrome: Novel Mutations in the OCRL1 Gene and Correlation of Direct DNA Diagnosis with Ocular ExaminationMolecular Genetics and Metabolism, 2000